BHPW
LCTX icon

Beverly Hills Private Wealth’s Lineage Cell Therapeutics LCTX Stock Holding History

Beverly Hills Private Wealth’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Hold
10,000
– – ﹤0.01% 254
2026
Q1 		$15.8K Hold
10,000
– – ﹤0.01% 346
2025
Q4 		$16.7K Hold
10,000
– – ﹤0.01% 334
2025
Q3 		$16.9K Buy
+10,000
New +$11.8K ﹤0.01% 343

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Beverly Hills Private Wealth's LCTX Position: Q2 2026 in Review

Beverly Hills Private Wealth held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 10,000 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #254.

Beverly Hills Private Wealth first reported a position in LCTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $16.9K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Beverly Hills Private Wealth held 10,000 shares of Lineage Cell Therapeutics worth $13.1K as of Q2 2026.
  • Beverly Hills Private Wealth left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Beverly Hills Private Wealth's portfolio in Q2 2026, its #254 holding.
  • Beverly Hills Private Wealth first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Beverly Hills Private Wealth's Lineage Cell Therapeutics position peaked at $16.9K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Beverly Hills Private Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.